KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Capital Employed: 2009-2025

Historic Return on Capital Employed for Neogenomics (NEO) over the last 15 years, with Sep 2025 value amounting to -0.09%.

  • Neogenomics' Return on Capital Employed fell 3.00% to -0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.09%, marking a year-over-year decrease of 3.00%. This contributed to the annual value of -0.07% for FY2024, which is negligibly% changed negligibly from last year.
  • Per Neogenomics' latest filing, its Return on Capital Employed stood at -0.09% for Q3 2025, which was down 14.13% from -0.08% recorded in Q2 2025.
  • Neogenomics' 5-year Return on Capital Employed high stood at -0.02% for Q2 2021, and its period low was -0.10% during Q3 2022.
  • Its 3-year average for Return on Capital Employed is -0.07%, with a median of -0.07% in 2024.
  • As far as peak fluctuations go, Neogenomics' Return on Capital Employed decreased by 8bps in 2022, and later climbed by 3bps in 2023.
  • Quarterly analysis of 5 years shows Neogenomics' Return on Capital Employed stood at -0.07% in 2021, then declined by 3bps to -0.10% in 2022, then increased by 3bps to -0.07% in 2023, then remained steady at -0.07% in 2024, then decreased by 3bps to -0.09% in 2025.
  • Its Return on Capital Employed was -0.09% in Q3 2025, compared to -0.08% in Q2 2025 and -0.07% in Q1 2025.